دورية أكاديمية
Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.
| العنوان: | Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. |
|---|---|
| المؤلفون: | Kumarasamy, Nagalingeswaran, Aga, Evgenia, Ribaudo, Heather J, Wallis, Carole L, Katzenstein, David A, Stevens, Wendy S, Norton, Michael R, Klingman, Karin L, Hosseinipour, Mina C, Crump, John A, Supparatpinyo, Khuanchai, Badal-Faesen, Sharlaa, Bartlett, John A |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2015 |
| المجموعة: | Duke University Libraries: DukeSpace |
| مصطلحات موضوعية: | ACTG 5230, intensification, protease inhibitor monotherapy, second-line antiretroviral therapy, Acquired Immunodeficiency Syndrome, Adult, Africa, Antiviral Agents, Asia, Developing Countries, Drug Therapy, Female, HIV-1, Humans, Lopinavir, Male, Middle Aged, Pilot Projects, Plasma, RNA, Viral, Ritonavir, Treatment Outcome, Viral Load, Young Adult |
| جغرافية الموضوع: | United States |
| الوصف: | BACKGROUND: The AIDS Clinical Trials Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficiency virus (HIV) regimens in Africa and Asia. METHODS: Eligible subjects had received first-line regimens for at least 6 months and had plasma HIV-1 RNA levels 1000-200 000 copies/mL. All subjects received LPV/r 400/100 mg twice daily. VF was defined as failure to suppress to <400 copies/mL by week 24, or confirmed rebound to >400 copies/mL at or after week 16 following confirmed suppression. Subjects with VF added emtricitabine 200 mg/tenofovir 300 mg (FTC/TDF) once daily. The probability of continued HIV-1 RNA <400 copies/mL on LPV/r monotherapy through week 104 was estimated with a 95% confidence interval (CI); predictors of treatment success were evaluated with Cox proportional hazards models. RESULTS: One hundred twenty-three subjects were enrolled. Four subjects died and 2 discontinued prematurely; 117 of 123 (95%) completed 104 weeks. Through week 104, 49 subjects met the primary endpoint; 47 had VF, and 2 intensified treatment without VF. Of the 47 subjects with VF, 41 (33%) intensified treatment, and 39 of 41 subsequently achieved levels <400 copies/mL. The probability of continued suppression <400 copies/mL over 104 weeks on LPV/r monotherapy was 60% (95% CI, 50%-68%); 80%-85% maintained levels <400 copies/mL with FTC/TDF intensification as needed. Ultrasensitive assays on specimens with HIV-1 RNA level <400 copies/mL at weeks 24, 48, and 104 revealed that 61%, 62%, and 65% were suppressed to <40 copies/mL, respectively. CONCLUSIONS: LPV/r monotherapy after first-line VF with FTC/TDF intensification when needed provides durable suppression of HIV-1 RNA over 104 weeks. CLINICAL TRIALS REGISTRATION: NCT00357552. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1537-6591 |
| العلاقة: | Clin Infect Dis; https://www.ncbi.nlm.nih.gov/pubmed/25694653Test; civ109; https://hdl.handle.net/10161/13768Test |
| الإتاحة: | https://hdl.handle.net/10161/13768Test https://www.ncbi.nlm.nih.gov/pubmed/25694653Test |
| رقم الانضمام: | edsbas.FFFD8064 |
| قاعدة البيانات: | BASE |
| تدمد: | 15376591 |
|---|